10x Genomics (TXG) Tops Q4 EPS by 14c

10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.15), $0.14 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $156.2 million versus the consensus estimate of $148.06 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• 10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target